Focus: Tolmar is a specialty biotech focused on small-molecule oncology and hormone-related therapies, with a highly concentrated revenue base anchored by a single commercial product.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Tolmar to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tolmar
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tolmar's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only commercial revenue driver for the company; accounts for 100% of reported revenue and patent protection through 2039.
Established franchise with multiple formulations; patent-protected until 2041, representing second pillar of commercial portfolio.
Extended-release leuprolide formulation in same franchise; patent protected through 2041.
ANDA filing suggests generic antipsychotic entry; pre-launch status indicates near-term potential upside.
2 discontinued, 4 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Based on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo